Related Experiment Videos
Waging war against pancreatic cancer: an interview with David Tuveson
1Cold Spring Harbor Cancer Center, Cold Spring Harbor, NY 11724, USA dtuveson@cshl.edu.
Abstract:
David Tuveson, Director of the Cancer Center at Cold Spring Harbor Laboratory, is a clinician-scientist with a longstanding interest in understanding and treating pancreatic cancer. Since developing the first mouse model of pancreatic cancer in 2002, the Tuveson lab has made a series of discoveries that shed light on the molecular drivers of this disease and provide promising therapeutic avenues for a malignancy that is notoriously challenging to treat. In collaboration with Hans Clevers, David developed the first pancreatic cancer organoids, which revolutionized the field by providing a powerful model system for basic discoveries and advancement of personalized medicine. Here, David talks to Ross Cagan about his path from chemistry student to world-renowned oncologist, highlighting how his colleagues, mentors and patient interactions shaped his research interests and unique approach to scientific discovery. As well as discussing the story behind some of his breakthroughs, he provides tips on running a lab and succeeding in or outside academia.
Insights
David Tuveson pioneered pancreatic cancer research with the first mouse model and organoids, advancing personalized medicine. His work illuminates molecular drivers and therapeutic strategies for this challenging malignancy.
Area of Science:
- Oncology
- Cancer Biology
- Translational Medicine
Background:
- David Tuveson's research focuses on understanding and treating pancreatic cancer.
- He developed the first mouse model of pancreatic cancer in 2002.
- Tuveson's lab investigates the molecular drivers of pancreatic cancer.
Discussion:
- The development of the first pancreatic cancer organoids, in collaboration with Hans Clevers, has revolutionized the field.
- Organoids provide a powerful model system for basic discoveries and personalized medicine.
- Patient interactions and mentorship have shaped Tuveson's scientific approach.
Key Insights:
- Discoveries shed light on molecular drivers of pancreatic cancer.
- Promising therapeutic avenues are being explored for pancreatic cancer treatment.
- Organoid technology advances basic research and personalized medicine.
Outlook:
- Continued exploration of therapeutic strategies for pancreatic cancer.
- Advancement of personalized medicine through innovative model systems.
- Insights into lab management and academic/non-academic career success.